에 대한 최신 뉴스 IGM Biosciences (NASDAQ:IGMS) 주식

IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Analyst Color

Broad U.S. Equity ETFs

Small Cap

ETFs

EVGO

IGMS

LNTH

MORF

OUST

PLSE

SOUN

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 2022년 1월 이후 최고 수준에 도달했다.

러셀 2000 지수, 연중 가장 강한 주를 기록하며 31개월 최고치를 기록

IGM Biosciences Inc

Barclays analyst David Anderson reinstates National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) with a Overweight and announces $16 price target.

News

Price Target

Initiation

Analyst Ratings

NESR

Barclays Reinstates Overweight on National Energy Services, Announces $16 Price Target

JP Morgan analyst Cory Carpenter initiates coverage on ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Overweight rating and announces Price Target of $55.

JP Morgan Initiates Coverage On ODDITY Tech with Overweight Rating, Announces Price Target of $55

In the first quarter of 2025, earnings are expected to remain weak due to delayed entry into the flagship system-on-a-chip (SoC) market. However, demand for core products such as image sensors and DDI is expected to increase on the back of flagship smartphone launches.
Looking ahead to the first quarter of 2025, earnings are expected to remain weak due to sluggish mobile demand and fixed-cost burden stemming from lower utilization rates.
 &nbsp;

Guidance

SSNLF

Reported Earlier, Samsung Expects Overall Memory Market Demand To Recover From Q2; Expects Earnings To Remain Weak In Q1

JP Morgan analyst Jeffrey Zekauskas upgrades Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) from Neutral to Overweight and lowers the price target from $210 to $205.

Upgrades

JP Morgan Upgrades Avery Dennison to Overweight, Lowers Price Target to $205

Baird analyst Benjamin Hartford downgrades United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) from Outperform to Neutral and lowers the price target from $160 to $130.

Downgrades

Baird Downgrades United Parcel Service to Neutral, Lowers Price Target to $130

The Company posted KRW 75.8 trillion in consolidated revenue and KRW 6.5 trillion in operating profit in the quarter ended December 31, 2024. For the full year, it reported KRW 300.9 trillion in annual revenue and KRW 32.7 trillion in operating profit.
 &nbsp;

Earnings

Reported Earlier, Samsung Electronics Says Q1 Overall Earnings Improvement May Be Limited Due To Weakness In Semiconductors Business

Jefferies analyst Christopher LeFemina initiates coverage on Core Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNR#NYSE">CNR</a>) with a Hold rating and announces Price Target of $93.

Jefferies Initiates Coverage On Core Natural Resources with Hold Rating, Announces Price Target of $93

Canaccord Genuity analyst Sumant Kulkarni downgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Buy to Hold and raises the price target from $119 to $132.

ITCI

Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold, Raises Price Target to $132

Global payment technology companies, Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) and Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), which process credit card payments and other financial transactions reported better-than-expected quarterly earnings on Thursday. Shall investors buy, sell or hold these companies? Here&#8217;s what technical analysis suggests.
<h3 class="wp-block-heading">Technical Analysis Of Visa And Mastercard</h3>
Technical analysis suggests both Visa and Mastercard stocks are currently overbought, indicating a potential correction may be imminent, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
Visa shares closed Thursday at $343.05, significantly above its eight-day simple moving average of $331.69, 20-day average at $320.65, also 50 and 200-day averages of $316.42, and $285.73, respectively. The relative strength index of 80.35 further reinforces this overbought condition, suggesting recent rapid price increases may be unsustainable.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-1024x576.png" alt="" class="wp-image-759794" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/news/earnings/25/01/43355517/visa-shares-rise-on-solid-q1-results-details">Visa Shares Rise On Solid Q1 Results: Details</a> 
Mastercard shares, on the other hand, also exhibited a similar trend, closing Thursday at $566.01. This price is well above its eight-day average of $541.60, and 20-day average of $526.54. Also, 50 and 200-day averages of $526.67 and $484.31, respectively. With an RSI of 76.67, Mastercard&#8217;s stock is also considered overbought, signaling potential exhaustion of upward momentum and a possible sell signal.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-1024x576.png" alt="" class="wp-image-759795" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/news/earnings/25/01/43345282/mastercard-q4-earnings-revenue-and-eps-beat-strong-growth-in-payments-and-cross-border-transactions">Mastercard Q4 Earnings: Revenue And EPS Beat, Strong Growth In Payments and Cross-Border Transactions</a>
<h3 class="wp-block-heading">Analyst Recommendations</h3>
Despite the warning signs from the technical analysis of daily moving averages, ratings based on analysts tracked by Benzinga have a consensus &#8216;buy&#8217; on both stocks.
Visa also enjoys a consensus &#8220;buy&#8221; rating. The average price target among <a href="https://www.benzinga.com/quote/V/analyst-ratings">34 analysts</a> is $324.06, with a range of $252 to $375. Recent ratings from Piper Sandler, BofA Securities, and Citigroup suggest a $351 target, implying a 0.90% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/V/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="379" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1-1024x379.png" alt="" class="wp-image-759801" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1-1024x379.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1-300x111.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1-768x284.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1.png 1062w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/25/01/43376448/elon-musks-x-money-to-see-about-600-million-active-monthly-users-via-visa-direct-integration">Elon Musk&#8217;s &#8216;X Money&#8217; To See About 600 Million Active Monthly Users Via Visa Direct Integration: &#8216;Excited To Partner,&#8217; Says CEO</a>
For Mastercard, the average price target among <a href="https://www.benzinga.com/quote/MA/analyst-ratings">34 analysts</a> is $542.84, with estimates ranging from $424 to $654. Recent ratings from Piper Sandler, Citigroup, and Oppenheimer suggest a $587.67 target, implying a potential upside of 3.53%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/MA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="386" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1-1024x386.png" alt="" class="wp-image-759797" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1-1024x386.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1-768x290.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1.png 1060w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Price Action: Shares of Visa were up 1.41% and Mastercard advanced 0.29% in premarket on Friday. Whereas the exchange-traded fund tracking S&amp;P 500, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.49% at $608.01.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43377987/after-imposing-tariffs-on-canada-donald-trump-threatens-100-levy-on-brics-for-move-against-dollar-how-will-us-manage-production-from-slippers-to-ships-asks-expert">After Imposing Tariffs On Canada, Donald Trump Threatens 100% Levy On BRICS For Move Against Dollar: &#8216;How Will US Manage Production From Slippers To Ships?,&#8217; Asks Expert</a></li>
</ul>
Image Via Shutterstock

Equities

Market Summary

Futures

Technicals

Markets

Trading Ideas

General

Mastercard Vs. Visa: Buy, Sell Or Hold? Here's What Technical Analysis Suggest

Qudian Announced Appointment Of Marcum Asia CPAs As Company's New Independent Registered Public Accounting Firm

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Neutral&#8221; zone on Thursday.
U.S. stocks settled higher on Thursday, with the Dow Jones index gaining more than 150 points as investors assessed the recent earnings reports from mega-cap tech stocks.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reported weaker-than-expected fourth-quarter earnings and sales results. The company, meanwhile, said it expects its vehicle business to return to growth in 2025. Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reported better-than-expected fourth-quarter sales results on Wednesday. Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported its second-quarter GAAP earnings of $3.23 per share, beating the $3.11 consensus estimate.
President Donald Trump confirmed Thursday the United States will impose 25% tariffs on imports from Canada and Mexico starting Saturday, Feb. 1.
On the economic data front, U.S. initial jobless claims fell by 16,000 from the previous week to 207,000 in the week ending January 25, compared to market estimates of 220,000. The U.S. economy expanded at an annualized rate of 2.3% in the fourth quarter, down from 3.1% in the previous quarter and versus market estimates of 2.6%.
Most sectors on the S&amp;P 500 closed on a positive note, with utilities, real estate and health care stocks recording gains on Thursday. However, information technology stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 169 points to 44,882.13 on Thursday. The S&amp;P 500 rose 0.53% to 6,071.17, while the Nasdaq Composite rose 0.25% at 19,681.75 during Thursday's session.
Investors are awaiting earnings results from Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) today.
At a current reading of 48.1, the index remained in the &#8220;Neutral&#8221; zone on Thursday, versus a prior reading of 46.5.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43336168/jim-cramer-likes-this-tech-stock-terrific-business-niche-business">Jim Cramer Likes This Tech Stock: &#8216;Terrific Business, Niche Business&#8217;</a></li>
</ul>

Pre-Market Outlook

MSFT

TSLA

Dow Jumps Over 150 Points As Investors Monitor Earnings Reports; Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone

Shares of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose sharply in today's pre-market trading after the company reported <a href="https://in.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">better-than-expected first-quarter results.</a>
Apple reported fiscal first-quarter revenue of $124.3 billion, beating analyst estimates of $124.13 billion. The iPhone maker reported first-quarter adjusted earnings of $2.40 per share, beating analyst estimates of $2.36 per share.
Apple shares gained 3.4% to $245.73 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Trident Digital Tech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) gained 104% to $1.94 in pre-market trading after dipping 62% on Thursday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) rose 63.4% to $2.55 in pre-market trading after announcing a partnership to advance subsea autonomy solutions.</li>
<li>Diginex Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) gained 40% to $49.01 in pre-market trading after dipping 30% on Thursday.</li>
<li>Orangekloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) gained 37.2% to $1.88 in pre-market trading. Maxim Group analyst Allen Klee initiated coverage on Orangekloud Technology with a Buy rating and announced a price target of $5.</li>
<li>Cyclerion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) rose 25.1% to $3.18 in pre-market trading after gaining 7% on Thursday.</li>
<li>Envirotech Vehicles, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) shares jumped 17.7% to $0.4077 in pre-market trading after dipping 48% on Thursday. Envirotech Vehicles recently announced it has received orders for 48 vehicles to New Jersey.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) gained 20.9% to $5.68 in pre-market trading after the company announced a $50 million investment from Softbank.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) rose 18.9% to $317.40 in pre-market trading after the company reported better-than-expected second-quarter financial results.</li>
<li>Kimball Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KE#NASDAQ">KE</a>) gained 11% to $20.11 in pre-market trading. Kimball Electronics will report second quarter fiscal year 2025 financial results on Tuesday, Feb. 4, 2025, after the closing bell.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aviat Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) shares fell 46.5% to $10.00 in pre-market trading. Aviat Networks will release its second quarter fiscal 2025 financial results for the period ended Dec. 27, 2024, on Feb. 4, 2025, after the closing bell.</li>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) dipped 39.7% to $2.35 in pre-market trading after the company priced $5 million public offering of 1.67 million common stock &amp; warrants at $3.00/share.</li>
<li>Stabilis Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) shares fell 19.7% to $6.00 in pre-market trading.</li>
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) fell 19.1% to $0.3202 in today's pre-market trading.</li>
<li>Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) shares dipped 18.7% to $3.21 in pre-market trading. Benson Hill shares jumped 119% on Thursday after the company announced results from a controlled broiler feeding trial conducted with Tyson Foods.</li>
<li>American Strategic Investment Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) shares tumbled 17.8% to $8.01 in pre-market trading.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) fell 15.1% to $189.32 in pre-market trading after the company reported third-quarter results.</li>
<li>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) fell 10.4% to $10.28 in pre-market trading after the company suspended its quarterly dividend.</li>
<li>Beazer Homes USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BZH#NYSE">BZH</a>) declined 8.6% to $25.33 in pre-market trading following worse-than-expected reported first-quarter financial results.</li>
<li>Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) fell 8.4% to $29.44 in pre-market trading following fourth-quarter earnings results.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/25/01/43335398/wall-streets-most-accurate-analysts-spotlight-on-3-risk-off-stocks-delivering-high-dividend-yields"> Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields</a></li>
</ul>

Movers

AAPL

AVNW

BHIL

CIFR

CYCN

DECK

DGNX

ENVB

EVTV

KITT

KLTO

ORKT

SLNG

TDTH

TEAM

Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

On Thursday, Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) launched its RTX 5090 and 5080 graphics cards, only to see them sell out almost immediately.
What Happened: The highly anticipated Nvidia Series 5000 GPUs sold out rapidly, leaving many gamers frustrated, <a href="https://in.ign.com/nvidia-rtx-5080/223698/news/nvidia-rtx-5090-and-5080-sell-out-instantly-and-scalpers-are-already-cashing-in-with-6000-ebay-listi">reported</a> IGN. The GPUs were anticipated to have limited availability, a fact Nvidia had previously warned about.
Despite the warning, eager buyers lined up at <a href="https://www.benzinga.com/tech/25/01/43242360/jensen-huang-mania-mirrors-taylor-swift-people-are-camping-outside-retailers-for-nvidia-5000-series-gpus">U.S. distributor Micro Center</a>, hoping to secure one of the coveted cards.
However, the limited stock led to scalpers listing the RTX 5090 on eBay for over $6,000, a significant markup from its $1,999 MSRP, the report noted.
See Also: <a href="https://www.benzinga.com/markets/25/01/43377131/tim-cook-wont-say-how-apple-plans-to-handle-trumps-tariff-policies-but-heres-whats-at-stake-for-the-iphone-maker">Tim Cook Won&#8217;t Say How Apple Plans To Handle Trump&#8217;s Tariff Policies — But Here&#8217;s What&#8217;s At Stake For The iPhone Maker</a>
Third-party manufacturers also increased prices, with the Asus ROG Astral model reaching $2,799.
As a result, gamers expressed their frustration online, with some calling it a &#8220;paper launch&#8221; due to the lack of available stock.
Why It Matters: The scarcity of these GPUs is partly due to a design flaw in Nvidia&#8217;s Blackwell-based processors. This flaw affected production yields, impacting the availability of the RTX 5090 and 5080.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Nvidia&#8217;s focus on data center chips, which share the same manufacturing process, further strained consumer GPU production, the report stated.
Nvidia is expected to report its fourth-quarter earnings on Feb. 26. Last quarter, it posted a <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">revenue of $35.1 billion</a>, marking a 94% year-over-year surge and surpassing Wall Street's consensus estimate of $33.12 billion.
Price Action: Nvidia&#8217;s stock dipped 1.16% in pre-market trading to $123.20 on Friday after closing at $124.65 up 0.77% during regular hours on Thursday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43221770/apples-ipad-turns-15-today-heres-a-throwback-to-when-steve-jobs-explained-called-it-the-third-category-after-phones-and-notebooks" target="_blank" rel="noreferrer noopener">Apple's iPad Turns 15 Today: Here's A Throwback To When Steve Jobs Explained Called It The ‘Third Category' After Phones And Notebooks</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Tech

Media

NVDA

Nvidia RTX 5090 And 5080 Sell Out Instantly — Scalpers Jack Up Prices To $6,000 As Gamers Face 'Paper Launch' Frustration

Macro Economic Events

Econ #s

Economics

Germany Unemployment Rate For January 6.2% Vs. 6.2% Est.; 6.1% Prior

Germany Unemployment Change For January 11K Vs. 14K Est.; 10K Prior

Stifel analyst J. Bruce Chan upgrades C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) from Hold to Buy and maintains the price target from $113 to $113.

CHRW

Stifel Upgrades C.H. Robinson Worldwide to Buy, Maintains Price Target to $113

Former Department of Government Efficiency (DOGE) co-leader Vivek Ramaswamy has clarified his departure from the organization, emphasizing a strategic pivot toward elected office while <a href="https://www.benzinga.com/news/25/01/43078027/vivek-ramaswamy-expected-to-exit-trumps-doge-task-force-amid-ohio-governor-bid-report">addressing speculation about his relationship</a> with Tesla Inc. CEO Elon Musk.
What Happened: Speaking on the Flagrant podcast, Ramaswamy detailed his evolving approach to government reform. &#8220;If you want to save a lot of money, you got to do it through legislation,&#8221; Ramaswamy said, highlighting his focus on legal and constitutional issues.
The entrepreneur-turned-politician defended his exit, which had sparked rumors of tension with Musk, by explaining the natural divergence in their approaches. While Musk continues to lead DOGE&#8217;s technology-centric strategy, Ramaswamy expressed his intention to pursue reform through elected office, particularly at the state level.
During the interview, Ramaswamy criticized the current regulatory landscape, pointing to unelected bureaucrats&#8217; outsized influence on policy. &#8220;Most of the laws that decide what you can and can&#8217;t do in your life were actually never passed by Congress,&#8221; he noted, citing examples ranging from fishing licenses to nuclear plant permissions.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Vivek: Kicked out of DOGE? Elon Beef? Trump Relationship and More" width="500" height="281" src="https://www.youtube.com/embed/6dOfkRLWD7M?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
See Also: <a href="https://www.benzinga.com/government/regulations/25/01/43377987/after-imposing-tariffs-on-canada-donald-trump-threatens-100-levy-on-brics-for-move-against-dollar-how-will-us-manage-production-from-slippers-to-ships-asks-expert">After Imposing Tariffs On Canada, Donald Trump Threatens 100% Levy On BRICS For Move Against Dollar: &#8216;How Will US Manage Production From Slippers To Ships?,&#8217; Asks Expert</a>
Why It Matters: While stopping short of a formal announcement, Ramaswamy indicated his political aspirations would be revealed &#8220;in the next couple of weeks.&#8221; His comments particularly highlighted the governor&#8217;s role in driving executive action, suggesting a potential bid for Ohio&#8217;s governorship.
The transition marks a significant shift for Ramaswamy, who sees state-level executive positions as crucial leverage points for implementing meaningful government reform. His focus appears to be on addressing both federal and state-level regulatory challenges through elected office rather than through organizational reform efforts.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43377455/trumps-tariffs-could-force-us-to-buy-venezuelan-oil-theres-no-other-option-on-the-table-says-canadas-foreign-minister">Trump&#8217;s Tariffs Could Force US To Buy Venezuelan Oil: &#8216;There&#8217;s No Other Option On The Table,&#8217; Says Canada&#8217;s Foreign Minister Melanie Joly</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Social Media

Vivek Ramaswamy Clarifies DOGE Exit Amid Speculation Of Sour Ties To Elon Musk, Shifts Focus To Ohio Governorship Bid: 'You Have to Do It Through Legislation'

NIO Says Has Completed Its Previously Announced Repurchase Right Offer Relating To Its 0.50% Convertible Senior Notes Due 2027

Goldman Sachs analyst Michael Ng maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Buy and lowers the price target from $50 to $44.

CMCSA

Goldman Sachs Maintains Buy on Comcast, Lowers Price Target to $44

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has marked the option for white interiors as sold out on its launch series of the refreshed <a href="https://www.benzinga.com/tech/25/01/43221344/tesla-model-y-pricing-evolution-cuts-hikes-refreshes-over-two-years">Model Y vehicle</a> in the U.S., even before deliveries have commenced. 
What Happened: Tesla launched the refreshed Model Y in the U.S.<a href="https://www.benzinga.com/tech/25/01/43183608/tesla-launches-refreshed-model-y-in-us-with-25-price-hike-full-self-driving-included"> earlier this month</a>. Deliveries of the launch series of the long-range all-wheel drive variant of the refreshed vehicle, priced at $59,990, are slated to start in March. 
Launch series refers to a limited edition of the vehicle with exclusive badging and more that the company intends to make to celebrate the start of production. 
However, the option for customizing the Launch series vehicle with white interiors is already marked as sold out on Tesla&#8217;s U.S. website. Customers now have only the option to opt for an all-black five-seat interior. 
As for exterior paint options, the company has listed just quicksilver, ultra red, pearl white multi-coat, and stealth grey in the U.S. In China, however, the company has also listed an option for glacier blue exterior paint on the vehicle. 
Why It Matters: Tesla CEO Elon Musk&nbsp;said on Wednesday that all of the company's many factories will start producing the new Model Y vehicle starting in February but will <a href="https://www.benzinga.com/25/01/43328898/elon-musk-warns-teslas-new-model-y-will-result-in-several-weeks-of-lost-production-for-ev-giant-in-q1">lose production in the days of retooling factory.</a>
The CEO also warned that margins will be impacted due to idle capacity and other ramp-related costs. However, these challenges will be overcome once production is ramped, he said.
While in the U.S., the refreshed vehicle is listed alongside older versions of the vehicle, in China, it replaced the older version. In both geographies, deliveries are slated to start in March.
Model Y is manufactured at Tesla's factory in California, as well as its gigafactories in Shanghai, Berlin, and Texas. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43375903/tesla-researcher-estimates-drop-in-ev-deliveries-for-2025-despite-promise-of-new-models">Tesla Researcher Predicts Drop In Deliveries For Elon Musk&#8217;s EV Giant In 2025 Despite New Model Launches</a></li>
<li></li>
</ul>
Image via Tesla

Tesla Marks White Interiors On Launch Series Of Refreshed Model Y As Sold Out Before Deliveries Begin

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

AMD downgraded, Nike upgraded: Wall Street's top analyst calls

Truist analyst Asthika Goonewardene lowered the firm's price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the shares....

IGM Biosciences price target lowered to $2 from $12 at Truist

IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company's sha...

Jefferies downgrades IGM Biosciences (IGMS) to a Hold

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical ...

IGM Biosciences downgraded to Hold from Buy at Jefferies

IGM Bio plunges as Wall Street downgrades on portfolio shakeup

IGM Biosciences Stock: Bad News With No Turnaround In Sight

IGM Biosciences ( ($IGMS) ) just unveiled an update. IGM Biosciences announced a strategic update to halt the development of two antibody therapies...

IGM Biosciences Halts Antibody Therapies, Cuts Workforce

JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing disconti...

IGM Biosciences upgraded to Neutral from Underweight at JPMorgan

Bank of America Securities analyst Charlie CY Yang maintained a Hold rating on IGM Biosciences (IGMS – Research Report) today. The company's shares...

Bank of America Securities Sticks to Their Hold Rating for IGM Biosciences (IGMS)

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

ACHR

APPF

CART

DTIL

GILD

HIMS

JOBY

MRSN

NWSA

NXPI

PINS

RPRX

SHOP

SNYNF

Press Releases

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Treatment.com AI Inc. (TRUE.CN) Advances AI in Healthcare with Strategic Moves

Health Care

IGM Biosciences to Present at the Jefferies Healthcare Conference

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

IGM Biosciences to Present at Three Upcoming Investor Conferences

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

AKTS

BNED

CSE:TRUE

GWAV

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Agenus

Aligos Therapeutics

Anixa Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Avalo Therapeutics

Cibus

Coya Therapeutics

Citius Oncology

Cue Biopharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

HilleVax

I-MAB

Immunic

Inozyme Pharma

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Pyxis Oncology

Tenaya Therapeutics

Vigil Neuroscience

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Jefferies

Truist Securities

Stifel

RBC Capital

BMO Capital

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 <a href="https://www.benzinga.com/topic/small-caps" target="_blank" rel="noopener" data-google-interstitial="false">2022년 1월 이후</a> 최고 수준에 도달했다.
이러한 랠리는 주로 목요일 세션에 의해 주도되었으며, 러셀 2000 지수는 일일 3.6%라는 놀라운 상승률을 기록했다. 이번 급등은 예상보다 낮은 6월 인플레이션 데이터에 따른 것이며, 이로 인해 잠재적인 금리 인하 가능성에 대한 기대가 강화되었다.
그러나 LPL 파이낸셜의 최고 글로벌 전략가인 퀸시 크로스비(Quincy Krosby)는 러셀 2000의 금리 인하 메시지가 &#8220;노동 시장에 대한 연방준비제도(연준)의 우려로 인해 흐려질 수 있다&#8221;고 시사하면서 주의를 조언했다.
크로스비는 노동시장 약화가 경제적으로 민감한 러셀 2000 지수에 여전히 타격을 줄 것이며, 금리 인하가 반드시 더 광범위한 경기 둔화로부터 지수를 보호할 수는 없을 것이라고 생각한다.
<h2 class="wp-block-heading">이번 주의 차트: 8개월 만에 최대 성과를 올린 소형주 지수</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-434094" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-768x366.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1536x732.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21.png 1920w" alt="" width="1024" height="488" /></figure>
출처: <a href="URL http://www.benzinga.com/pro/register/?utm_source=BZprocontent071224&amp;t=be2bearmibe3na1">Benzinga Pro</a>
러셀 2000의 인상적인 성과는 투자자들이 거대 기술 기업들에서 벗어나 더 넓은 시장으로 직접 유입됨에 따라 금리에 민감한 중소형주가 이익을 얻는 등 시장 초점의 상당한 변화를 강조한다고 크로스비가 강조했다.
이 분석가는 러셀 2000이 잠재적인 금리 완화와 광범위한 경제 상황에 대한 중요한 지표 역할을 한다고 지적했다. 일반적으로 중소형주 유니버스는 매력적인 밸류에이션에도 불구하고 심각한 경기 둔화 조짐이 보이면 매도할 것이다.
"역사적으로 러셀 2000은 첫 번째 금리 인하 이후 3개월 동안 시장보다 뒤쳐졌다. 연준이 일반적으로 경제, 특히 노동 시장에 대한 우려로 금리를 인하하기 때문이다. 파월 의장은 연준의 최대 고용 의무화를 계속해서 주장하면서 연준이 경제 지원을 위해 더 빠른 속도로 금리를 인하할 것이라는 점을 분명히 했다"고 그녀가 말했다.
노동 시장 상황이 악화되면 연준은 예정된 9월 18일 회의보다 더 빨리 완화 주기를 시작할 수도 있다고 크로스비는 말했다. 시장에서는 경기 호조 속에서 인플레이션 완화에 따른 금리 인하를 선호하고 있다.
<h2 class="wp-block-heading">이번 주 러셀 2000에서 가장 높은 성과를 기록한 상위 10개 회사 </h2>
<ol>
<li>모픽 홀딩 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>): 75.16% (헬스케어)</li>
<li>랜티우스 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>): 55.47% (헬스케어)</li>
<li>IGM 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>): 54.22% (헬스케어)</li>
<li>사운드하운드 AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>): 52.63% (정보기술)</li>
<li>메소드 일렉트로닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NASDAQ">MEI</a>): 47.96% (정보기술)</li>
<li>솔라리스 오일필드 인프라스트럭처 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOI#NYSE">SOI</a>): 46.87% (에너지)</li>
<li>펄스 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>): 45.98% (헬스케어)</li>
<li>아우스터 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>): 44.21% (정보기술)</li>
<li>EV고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>): 42.65% (소비자 자유롭게 선택 가능한 소비재)</li>
<li>선런 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>): 42.51% (산업재)</li>
</ol>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39750466/us-consumer-morale-dips-more-than-expected-in-july-sentiment-remains-stubbornly-subdued">미국 소비자 심리, 7월 예상보다 감소&#8230;전망은 &#8216;완고하게 억제된 상태&#8217;</a></li>
</ul>
사진: 셔터스톡
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

IGM Biosciences

뉴스

에 대한 최신 뉴스 IGM Biosciences (NASDAQ:IGMS) 주식

금요일, 7월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌